1Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts. 2Department of Life Sciences, Korea University, Seoul, Republic of Korea.
Copyright held by the owner/author(s).
Copyright held by the owner/author(s).
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
1Genome Research Center, GC Genome, Yongin-si, South Korea. *Corresponding Author: Eun-Hae Cho, Genome Research Center, GC Genome, 107, Ihyeon-ro 30 beon-gil, Yongin-si, 16924, South Korea. E-mail: ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Major Finding: Synonymous mutations can promote tumorigenesis by deregulating RNA modifications of tumor suppressors.
1Department of Communication, University of Utah, Salt Lake City, Utah. 2Huntsman Cancer Institute, Salt Lake City, Utah. *Corresponding Author: Yi Liao, Department of Communication, University of ...
Waltham, MA–based biotech Mural Oncology announced that it will end its phase III trial of nemvaleukin alfa, an engineered fusion protein that selectively binds to the intermediate-affinity IL2 ...
Boston, MA–based Dana-Farber Cancer Institute (DFCI) secured approval from the state to build a 300-bed hospital at the current site of the Joslin Diabetes Center in the city’s Longwood Medical Area.
Search for other works by this author on: ...
A new study in mice shows that COX-1 inhibitors, such as aspirin, block a platelet-mediated pathway that cancer cells use to evade immune detection and spread to other tissues. By reducing TXA2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback